ABBOTT PARK, Ill. – Global health care company Abbott has announced CE Mark and first use of its new Confirm Rx Insertable Cardiac Monitor, a smartphone-compatible device that will help physicians identify difficult to detect cardiac arrhythmias to help guide therapy. After receiving CE Mark, the device was successfully implanted into a patient at the Herz-und Diabeteszentrum NRW, Ruhr-University of Bad Oeynhausen, Germany. “Incorporating wireless technology directly into our devices enhances the quality of remote monitoring and patient compliance,” said Dr. Mark Carlson, chief medical officer of Abbott’s cardiac arrhythmias and neuromodulation businesses, in a statement. The Confirm Rx ICM is designed to continuously monitor a patient’s heart rhythm and proactively transmit information through the myMerlin mobile app. Patients can record symptoms directly on their smartphone without the need for a bedside transmitter or separate activator. The device is currently under review by the U.S. Food & Drug Administration.
You are here: / / Abbott announces CE Mark and first use of smartphone-compatible cardiac monitor